Clinical status of carboplatin
Canetta, R.; Franks, C.; Smaldone, L.; Bragman, K.; Rozencweig, M.
Oncology 1(5): 61-70
1987
ISSN/ISBN: 0890-9091 PMID: 3079484 Document Number: 305416
Carboplatin, a cisplatin derivative, shows promise of being an effective weapon against ovarian, cervical, and small-cell lung cancer, as well as epidermoid cancer of the head and neck, with fewer toxic effects than cisplatin. It has successfully completed phase III investigation and clinical trials continue.
Document emailed within 1 workday
Related Documents
Vapattanawong, P. 2006: A comparative study on hematological effects of carboplatin plus cyclophosphamide and carboplatin plus paclitaxel chemotherapy for the first line treatment of epithelial ovarian cancer Journal of the Medical Association of Thailand 89(9): 1357-1361Kosmidis, P.; Mylonakis, N.; Fountzilas, G.; Samantas, E.; Athanassiadis, A.; Pavlidis, N.; Skarlos, D. 1997: Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study Seminars in Oncology 24(4 Suppl 12: S12
Skarlos, D.V.; Aravantinos, G.; Kosmidis, P.; Athanassiadis, A.; Stathopoulos, G.P.; Pavlidis, N.; Bafaloukos, D.; Karphathios, S.; Papakostas, P.; Bamia, C.; Fountzilas, G. 1997: Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study Seminars in Oncology 24(5 Suppl 15: S15
Van Echo, D.A.; Egorin, M.J.; Whitacre, M.Y.; Olman, E.A.; Aisner, J. 1984: Phase I clinical and pharmacologic trial of carboplatin daily for 5 days Cancer Treatment Reports 68(9): 1103-1114
Ohno, M.; Hirokawa, M.; Hando, T. 1992: Pharmacokinetics of carboplatin after intraperitoneal administration and clinical effect in ovarian cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(14): 2355-2361
Natale, R.B. 1996: Preliminary results of a phase I/Ii clinical trial of paclitaxel and carboplatin in non-small cell lung cancer Seminars in Oncology 23(6 Suppl 16: 51-54
Coughlin, C.T.; Richmond, R.C. 1989: Biologic and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin Seminars in Oncology 16(4 Suppl 6: 31-43
Shinohara, C.; Matsumoto, K.; Kuriyama, M.; Adachi, H.; Ono, Y.; Higashi, H.; Furuta, T.; Ohmoto, T. 1994: Clinical pharmacokinetics of carboplatin and MCNU in malignant brain tumor and normal brain tissues Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(8): 1163-1168
Khmel'nitskaia, N.M.; Lantsov, A.A. 1998: Clinical-morphological assessment of the functional status of tonsils in clinical manifestations of chronic tonsillitis Vestnik Otorinolaringologii 5: 38-39
Adebami, O. 2016: Relationship between Ponderal Index, Mid-Arm Circumference/ Head Circumference Ratio and Clinical Assessment of Nutritional Status Score (CANSCORE) in the Determination of Nutritional Status of Newborn at Birth in Nigeria International Journal of Child Health and Nutrition 5(3): 112-120
Preusser, M.; Berghoff, A.S.; Manzl, C.; Filipits, M.; Weinhäusel, A.; Pulverer, W.; Dieckmann, K.; Widhalm, G.; Wöhrer, A.; Knosp, E.; Marosi, C.; Hainfellner, J.A. 2014: Clinical Neuropathology practice news 1-2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma Clinical neuropathology 33(1): 6-14
Ruckdeschel, J.C. 1994: The future role of carboplatin Seminars in Oncology 21(5 Suppl 12: 114-118
Geffen, D.B.; Cohen, Y. 1995: Cisplatin and carboplatin--update Harefuah 129(3-4): 131-135
Fujii, M.; Ohno, Y.; Tokumaru, Y.; Imanishi, Y.; Kanke, M.; Tomita, T.; Yamashita, T. 2000: UFT plus carboplatin for head and neck cancer Oncology 14(10 Suppl 9: 72-75
Tumol'skaia, N.I.; Kakliugina, M.L.; Tumol'skaia, T.V. 1991: The assessment of the clinical status of patients with alveolar hydatid disease by using statistical processing methods. 2. the correlation of laboratory tests at different disease stages and their clinical interpretation Meditsinskaia Parazitologiia i Parazitarnye Bolezni 5: 7-10
Danieu, L.; Warrell, R.P. 1986: Limited activity of carboplatin in malignant lymphoma Cancer Treatment Reports 70(7): 931-932
Nielsen, I.; Sartori, S.; Tassinari, D.; Pennacchio, G.; Calia, N.; Malacarne, P. 1992: Changes in plasma iron levels following Carboplatin administration International Journal of Oncology 1(7): 791-794
Fujita, Y.; Seki, N.; Inoue, K.; Miyazawa, T.; Eguchi, K. 2010: A comparison of cisplatin and carboplatin: a short review West Indian Medical Journal 59(1): 115
Kato, T.; Nishimura, H.; Yamabe, T.; Terashima, Y.; Kasamatsu, T.; Hirabayashi, K.; Nishiya, I.; Yajima, A.; Takamizawa, H.; Tsutsui, F. 1988: Phase Ii study of carboplatin in ovarian cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(8): 2291-2296
Kavanagh, J.J.; Nicaise, C. 1989: Carboplatin in refractory epithelial ovarian cancer Seminars in Oncology 16(2 Suppl 5: 45-48